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Hepatic haemangiomas account for about quarter of all benign tumours of the liver. In last 
few decades, lot of advances have been made in the field of diagnosis and management of 
these lesions. This article presents a case of hepatic haemangioma that is under follow-up 




Hepatic haemangioma and is the second most common tumour seen in the liver after 
metastases and accounts for 73% of all benign liver tumours with a frequency of 0.4-7.3% at 
autopsy1 . They are composed of masses of blood vessels with atypical or irregular in 
arrangement and size. They are also referred to as cavernous haemangiomas due to the 
cavernous vascular space seen in histological studies. These benign tumours are usually small, 
solitary or multiple, and asymptomatic2. 
 
Case presentation  
 
A 32 years old female, married with two children, reported with vague pain in upper abdomen 
of severity of 3/10 on Visual analogue scale. There was no significant past medical, surgical, 
drug-intake or family history. On examination, the vital signs were stable and the abdominal 
examination revealed no positive findings.  
 
Ultrasonogram of the Abdomen revealed the liver to be of average size (12 cm) with a 
homogenous parenchymal echo-pattern and normal calibre of portal vein and biliary tree. There 
was a well-defined hyperechoic lesion seen in the left liver lobe measuring about 3.5 X 2.5 x 2.8 
cm and the features were suggestive of haemangioma (Fig 1 ).  
 
Figure 1.  Ultrasonogram Depicting Hyperechoic Haemangioma in the Left Lobe of Liver 
 
CT scan of the abdomen and pelvis with IV and oral contrast revealed a 2.7 cm low-attenuation 
mass in Segment 5 of the liver (in right lobe) showing peripheral puddling of contrast in the 
portal venous phase characteristic of a haemangioma (Figure 2) . There were no other hepatic 
lesions or intra or extra hepatic biliary ductal dilatation .The gallbladder, spleen, pancreas and 
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Figure 2. Contrast enhance CT Scan depicting hepatic haemangioma (shown with red arrow)  in 
(A) Transverse plane (B) Sagital plane (C) Coronal plane . 
 
The first degree family members (parents, two siblings and two children) were screened by 
abdominal ultrasonography and were found to have no lesions. The patient was counselled 
under follow up, without any active intervention. USG studies repeated at follow up of one year 
revealed that the lesion had remained static in dimensions. 
 
Pathophysiology  
The aetiopathogenesis of hepatic haemangiomas is not understood completely. They are 
postulated to be vascular malformations or hamartomas of congenital origin that undergo 
enlargement by ectasia rather than by hypertrophy or hyperplasia. No definite familial or 
genetic mode of inheritance has been described though a few case series have been reported in 
literature, indicating some role for familial link.  
 
Moser et al2 presented a report of a large family of Italian origin where three female patients in 
three successive generations suffered from large symptomatic hepatic haemangiomas. In 
addition, two other female relatives exhibited asymptomatic haemangiomas on 
ultrasonography. The authors postulated that restriction of the disease to the females could be 
explained by sex-dependent differences in penetrance or expressivity of a presumable "liver-
haemangioma" gene or the production of proliferative factors, such as female sex hormones. 
The authors also observed an unexplained increased incidence of thyroid adenomas among 
members with or without hepatic haemangioma of the reported family. Diez Redondo P et al3 
described a family in which six members from three successive generations presented hepatic 
haemangiomas. One of the cases was taking oral contraceptives and had a painful giant 
haemangioma with biochemical abnormalities while the remaining cases were asymptomatic. Li 
P et al4 reported two siblings (a male and a female) with Dubin-Johnson syndrome with multiple 
hepatic haemangioma.  
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Several pharmacologic agents have been postulated to promote the growth or induce symptoms 
in haemangioma. These include female sex (endogenous /exogenous) hormones5,6 and steroids.  
Spitzer D et al7  reported asymptomatic increase in hepatic haemangioma in pregnant women 
following ovarian stimulation therapy with clomiphene citrate and human chorionic 
gonadotropin. Graham E et al8 reported a case of symptomatic hepatic haemangioma with 





The reported incidence rate varies widely and is approximately 2%. The prevalence rate at 
autopsy is as high as 2- 7.3% 1,8. The widespread use of non-invasive abdominal imaging 
modalities has led to increased detection of asymptomatic lesions in recent times. 
 
Sex 
Women, especially with a history of multiparity, are affected more often than men. The female-
to-male ratio reported in literature9 varies from 3-6:1. 
 
Age 
Hepatic haemangiomas can occur at all ages though 60 to 80 percent of cases are diagnosed in 
individuals aged 30-50 years. Female often present at a younger age and with larger lesion. 
Further the lesions responsible for symptoms are more likely in females6. Hepatic 
haemangiomas may be seen in infancy and have also been detected prenatally in a growing 
fetus. Isaacs10 studied 194 foetuses and neonates with hepatic tumours diagnosed prenatally (n 
= 56) and in the neonatal period (n = 138) and found haemangioma to constitute 60.3% 
(n=117) of cases.  
 
Pathology  
 Hepatic haemangiomas vary in size from a few millimetres to many centimetres though usually 
are 2-4 cm. 70-80% are solitary and the larger lesion may be pedunculated 11-12. 
On gross examination, the lesions appear as dark-purple cystic masses, which collapse when 
sectioned due to oozing out of blood. They can be found in either of the lobes of the liver, though 
are predominantly found in the right lobe. Lesions tend to be well circumscribed and often 
surrounded by a thin capsule /interface 13. The cut surfaces exhibit a red-brown appearance 
with a spongy consistency that may show haemorrhage, scarring, phleboliths or calcification.  
Microscopically, the tumour is composed of large (cavernous) vascular spaces of varying sizes, 
lined by a single layer flat tumour endothelial cells (which appear very similar to normal cells). 
The vascular compartments are separated by thin fibrous septae and may contain thrombi.  
Large haemangioma may show features of collagenous scars or fibrous nodules as thrombosis 
occurs and very rarely, there may be focal stromal calcification and ossification. 
 
Clinical presentation  
Haemangiomas are generally small, asymptomatic and discovered incidentally when the liver is 
imaged for unrelated conditions 14 or when the liver is examined at laparotomy or autopsy. 
Goodman15 in 1987 found that the symptoms are experienced by 40% of cases with greater than 
4-cm haemangioma and by 90% of cases with 10-cm haemangioma. Upper abdominal pain 
/discomfort or fullness is the most common complaint, when the lesion becomes symptomatic. 
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Less common complaints include nausea, anorexia, dyspepsia and early satiety, which are seen 
when large haemangiomas compression the adjacent organs 16.  
The pain is usually mild but can become severe due to thrombosis or bleeding within the lesion 
and associated stretching and inflammation of Glisson's capsule. Pain from an acute thrombosis 
can last up to three weeks and be associated with pyrexia and derangement of liver functions 17. 
Physical examination is generally normal and the only findings of significance, seen 
infrequently, are an enlarged liver or the presence of an arterial bruit over the right upper 
quadrant. 
 
The atypical presentations of hepatic haemangiomas include:  
1. High output cardiac failure from massive arteriovenous shunting, particularly in the 
children 18, 19.  
2.  jaundice from compression of the bile ducts 20,  
3. hypothyroidism refractory to hormone replacement therapy , due to the presence of 
high levels of 3-iodothyronine de-iodinase activity in the hemangioma, that catalyzes the 
conversion of thyroxine  and triiodothyronine to biologically inactive hormones, reverse 
triiodothyronine, and 3,3'-diiodothyronine25 
4. Gastrointestinal bleeding from haemobilia 21, 22, and   
5. Pyrexia of unknown origin 23, 24. 
6. polymyalgia rheumatica , resistant to steroids 26. 
7. Kasabach-Merritt syndrome (KMS) is a rare and severe coagulation disorder 
characterized by profound thrombocytopenia, microangiopathic hemolytic anemia, and 
consumption coagulopathy 27 -29 
 
  In children, cutaneous haemangiomas may serve as markers for hepatic haemangiomas.    
Huges JA et al30 found that asymptomatic hepatic haemangiomas occurred in nearly 25% of 




Hepatic haemangiomas have to be differentiated from other benign and malignant space-
occupying liver lesions. Benign lesions include cysts, adenomas, regenerating nodules, focal 
nodular hyperplasia, and abscesses and the malignant lesions include hepatocellular carcinoma, 
hepatic angiosarcoma and hepatic metastases. In histopathology, the specimen needs to be 
differentiated from: 
i. Hereditary hemorrhagic telangiectasia: the lesion has aberrant portal vessels with dilated 
vascular channels within portal tracts,  
ii. Infantile hemangioendothelioma: the lesion has cellular atypia. 
iii. Peliosis hepatis: the lesion has no fibrous septa 
 
Diagnosis 
 Hepatic haemangiomas have certain characteristics that point towards the diagnosis on 
ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) 31-32.  A 
minority of lesions are however atypical and may require multiple imaging tests or 
conventional arteriography or even  surgical intervention to achieve a confident diagnosis 33.  
Plain radiograph — Plain abdominal radiographs may be normal or may show evidence of 
calcification within the lesion. However this calcification lacks specificity in haemangiomas. 
Ultrasound — Ultrasound typically reveals a well-demarcated, hyperechoic, homogeneous, 
mass. Colour Doppler Sonography (CDS) can depict intratumoural flow and peritumoural 
hepato-fugal portal flow in patients with hepatic haemangiomas accompanied by arterioportal 
shunt 34.  
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Lim35 presented a series of 45 patients with hepatic haemangiomas and found the tumour depth 
to be a significant variable that affects the capability of CDS to depict such findings. The 
frequencies of intratumoural flow and peritumoural hepatofugal portal flow were as high as 
88% and 80% for shallow (≤30 mm) lesions, and they were 40% and 35% for deep (>30 mm) 
lesions (p=0.0012; p=0.0051). 
 
Contrast-enhanced ultrasound (CEUS) — Ultrasound contrast agents consist of gas-filled 
echogenic microbubbles that enhance the ultrasound signal produced by flowing blood. This 
variant of ultrasonography demonstrates typical haemangioma imaging characteristics, in form 
of peripheral nodular contrast enhancement and iris-diaphragm sign in a high percentage of 
patients with undetermined lesions thereby improving the noninvasive functional 
characterization and differentiation of haemangiomas36. 
Sirli R et al37 presented a series which proved that CEUS diagnosed correctly 90% of 
hemangiomas, all with typical enhancement pattern and  diagnosed additional 40% of 
 hemangiomas that could not be diagnosed  on the  standard ultrasound .Ryu SW et al38 found 
that  the sensitivity, specificity, and accuracy for CEUS were 94.6% that is comparable to CT and 
MRI and hence CEUS can be highly reliable if appropriate acoustic window is available .  
Computed tomography — A non-contrast-enhanced CT scan of a haemangioma usually 
demonstrates a well-demarcated hypo-dense mass. Calcifications may be seen in approximately 
10 % of lesions. The lesions may appear as hyperdense relative to the surrounding parenchyma 
in patients with fatty liver. The administration of contrast medium results in peripheral nodular 
or globular enhancement in the early phase (in up to 90- 94 percent of hemangiomas >4 cm in 
size), followed by a centripetal pattern or "filling in" during the late phase 39. After a delay of 
three or more minutes, the lesions classically opacify and remain isodense or hyperdense on 
delayed scans. Enhancement may however be absent in hemangiomas with large cystic areas or 
scar tissue. 
 
Recently a retrieval-based computer-aided diagnosis (CADx) system for the characterization 
of liver lesions in computed tomography (CT) scans has been introduced and in a study by 
Dankeri P et al 40, the stand-alone predictive performance of the CADx system was assessed and 
compared to that of three qualified radiologists who were provided with the same amount of 
image information to which the CADx system had the access and CADx system was found to be 
highly reliable.  
 
Magnetic resonance imaging — MRI has emerged in recent years as a highly accurate, non-
invasive technique for diagnosing haemangiomas because of its high contrast resolution, lack of 
ionizing radiation, and the possibility of performing functional imaging sequences 41.  
With advances in hardware and coil systems, this modality has a sensitivity and sensitivity of 
more than 94 percent.  Typically, the lesions have low signal intensity on T1-weighted images 
and are hyperintense on T2-weighted images. When gadolinium diethylenetriaminepentaacetic 
acid (Gd-DTPA) is used as a contrast agent, the lesions enhance in a fashion similar to that seen 
on dynamic CT displaying early peripheral discontinuous nodular or globular enhancement on 
arterial phase scans with progressive centripetal enhancement or "filling in" on delayed scans. 
Typically, haemangiomas follow the signal intensity of blood and the presence of intralesional 
fibrosis results in areas of low intensity on T2-weighted images. On High-b-value diffusion-
weighted, DW-MR Images, the lesions often show findings that suggest restricted diffusion 42.  
Duran R et al (43) in 2015 presented the results of a retrospective study of 89 patients with 231 
hepatic haemangiomas and found that the MR imaging characteristics of haemangiomas were 
similar in patients with normal compared to fibrotic and cirrhotic livers. Less T2 shine-through 
effect was seen in haemangiomas developed on cirrhosis, the latter being an important finding 
to highlight in these patients at risk of developing hepatocellular carcinoma.  
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Nuclear medicine studies — Technetium-99m pertechnetate-labeled red blood cell pool 
studies (99mTc-RBC pool studies)  is a highly specific imaging technique  for haemangiomas as 
its hypervascular nature may create equivocal result on CT or MRI 44.  
   
The study shows an initial hypoperfusion during arterial flow, which is followed by gradual 
increase of tracer peaking 30 to 50 minutes after the injection.  Delayed images display 
retention of the isotope within the lesion. The sensitivity of the method has been found to be 
about 76%, specificity 98%, positive predictive value 98% and negative predictive value 79%. 
With SPECT (single photon emission computerized tomography), sensitivity of the method 
increases to  95%, specificity 98%, positive predictive value 98% and negative predictive value 
94% 45. RBC SPECT/CT imaging using this hybrid SPECT/CT system is feasible and useful in the 
identification or exclusion of suspected hepatic haemangiomas located near regions with high 
blood activity like the inferior vena cava, the heart or hepatic vessels 46. 
 
Management 
Hepatic haemangioma are mostly small and asymptomatic at the time of diagnosis, and they do 
generally tend to remain so or grow very slowly for the rest of the life. In addition, malignant 
transformation of these lesions has not been reported in literature. Hence most hepatic 
haemangioma may be left safely alone.  However, there are rare cases in literature where the 
growth of these lesions has been rapid and consistent. Yoshida et al 47 reported an 11-fold 
growth in hepatic haemangioma over a period of 11 years, when the volume of the lesion had 
grown from 123 cc to 1343 cc. 
Radiologic study follow-up 
Once the diagnosis of hepatic haemangioma is confirmed by radiologic studies, opinion varies 
whether follow-up radiologic studies are warranted to reassess the size of the lesion. 
Yeh  et al 48 followed up 180 hepatic haemangiomas in 130 adult patients, for more than 5 years 
with at least twice ultrasound examinations and found that the diameter of 14 (7.7%) 
haemangiomas in 13 patients increased and the lesion volume doubling time of ranged from 
17.3 to 178.1 months. Kobayashi et al 49 evaluated consecutive ultrasonograms of 27 
haemangiomas in 23 patients over a follow-up period ranging from  12 to 114 months      
(average 44) and found that six (22.2%) haemangiomas changed in size, which included three 
lesions with increase in size, one lesion with decrease in size and two lesions with spontaneous 
regression. 
 
Hasan et al 50 in 2014 reported the results of a retrospective cohort study undertaken at an 
academic hospital tertiary referral centre to evaluate the growth rate of hepatic haemangiomas 
on cross-sectional imaging studies during a 10-year period (1997-2007). A total of 163 
haemangiomas were identified in 123 patients and the mean (SD) initial size was 3.2 (cm. 
During follow-up, 39.3% of haemangiomas grew 5% or more in mean linear dimension and the 
mean (SD) annual linear growth rate was found out to be 0.03 (0.21) cm for all lesions and 0.19 
(0.23) cm for those that grew 5% or more. By volume, 44.7% of lesions grew 5% or more and 
the mean (SD) annual volumetric growth rate was 2.8% (21.0%) for all lesions and 17.7% 
(22.8%) in those that grew 5% or more. The authors concluded that the overall rate of growth is 
slow but stressed the need for further research to determine the treatment modalities of the 
patients with more rapidly growing haemangiomas.  
 
Ng et al 51 studied the giant hepatic haemangiomas with the  median maximal diameter of the 
lesions was 5.5 cm (range, 4.0-20.3 cm ) in  42 female and 22 male patients with a median age of 
49 (range, 27-84) years . The median duration of follow-up was 34 months. Most (54%) of the 
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patients were asymptomatic, but in 17% the haemangioma enlarged to exceed its original size 
by more than 20%. There were no haemangioma-associated complications. The authors 
concluded that if the diagnosis is uncertain, selective further investigations may be necessary 
but the lesions with a confirmed diagnosis tend to remain static in size and hence performing 
regular scans for asymptomatic giant liver haemangiomas may not be necessary 
 
Medical treatment 
Since 1990s, some cases were reported to show shrinkage of hepatic haemangiomas after 
interferon therapy 52. In recent years, cases have been published which show reduction of 
haemangiomas by inhibition of growth factor and kinase. Mahajan D et al  (53) in 2008 reported 
an incidental reduction in the size of liver haemangioma following use of vascular endothelial 
growth factor (VEGF) inhibitor bevacizumab. 
 
Yamashita et al 54 reported the successful use of Sorafenib, multikinase inhibitor in the 
management of a 76-year-old man with a giant cavernous haemangioma measuring more than 
20 cm in diameter. Tumour volume reduced from 1492 mL at baseline to 665 mL after 78 days 
of treatment with sorafenib 600 mg/day. Reports have been published in recent literature that 
point towards the efficacy of low dose propranolol, a non-selective beta-blocker, in the 
management of infantile hepatic haemangiomas 55-56.  
 
Surgical Treatment 
The major indications for elective surgical management of hepatic haemangioma 57-59 include 
abdominal pain, extrinsic compression of adjacent structures, cardiac failure, coagulopathy etc., 
diagnostic uncertainty and rapid enlargement whereas bleeding after rupture (60) or needle 
biopsy mandates emergent surgical intervention.  
 
There are three procedures for surgical management of hepatic haemangiomas including: 
1. Liver resection 
2. Enucleation 
3. Liver transplantation 
The procedures are conducted by open approach or by minimally invasive 
(laparoscopic/robotic) approach1. The choice of the surgical procedure to be carried out 
depends upon the location and the morphology of the lesion 59. 
 
Martinez- Gonzalez et al 59 reported surgical management in 24 patients with symptomatic 
liver haemangiomas, 16 patients underwent liver resection (66.6%), and 8 lesions were 
enucleated (33.3%). Four patients (16.6%) presented operative complications including 
postoperative bleeding in two (8.3%), fever in one (4.1%) and abdominal haematoma in one 
(4.1%). There was no operative mortality. 22 patients (91%) achieved complete symptomatic 
relief. Demircan et al 58 operated upon 15 patients and 11 patients underwent enucleation of the 
lesion while the other 4 patients underwent resection procedures. Complications occurred in 2 
(13.4%) patients and 1 patient with the largest tumour (30cm) died of bleeding and 
coagulopathy.  One patient was lost to follow up and 12 out of the remaining 13 operated 
patients (92.3%) reported complete relief of symptoms. In the series of Kayaoglu et al 57, 
enucleation was found to be safe and effective operation in 18 haemangiomas ranging in size 
from 2-30cm (mean 12.7cm). Ozden et al61 and Popescu et al 62 also found enucleation to be 
rapid and safe and hence preferable over resection. But Guiliante et al 63 found resection and 
enucleation to be equally effective and safe and considered the size of the lesion to be 
responsible for complications rather than the choice of the procedure. Fu XH et al 64   presented 
the outcomes in 172 patients who underwent enucleation of hepatic haemangiomas. The lesions 
were centrally located in 76 patients (44.2%) and peripherally located in 96 patients 
(55.8%). The authors concluded that enucleation to be a safe surgery for haemangiomas in any 
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part of the liver, although it is technically more demanding for centrally than peripherally 
located haemangiomas. Baer et al 13 advocate routinely performing complete extra-hepatic 
ligation of the main arterial supply before attempting enucleation of a haemangioma to reduce 
blood loss and define the interface with the normal liver tissue. 
  
Farges et al 65 had 50% of the operated patients with persistent symptoms during follow up and 
hence stressed on proper preoperative selection and work-up to rule out other causes of 
abdominal symptoms. 
 
Liver transplantation has also been used successfully to treat selected symptomatic patients 
with unresectable giant or diffuse haemangiomas and haemangiomas associated with Kasabach-
Merritt syndrome 66-68. Surgical ligation of feeding vessels as a surgical technique is also 
mentioned in literature for the management of shunting liver haemangiomas that otherwise 
would rapidly lead to intractable cardiac failure. Rokitansky wt al69 in 1998 presented a 
successful usage of transhepatic compression sutures using polytetrafluoroethylene (PTFE) 
pledgets and selective ligation of large feeding vessels from right hepatic artery.  
Arterial embolization 
Surgical resection may not be technically safe or possible in certain cases due to the massive or 
diffuse nature of the lesion, proximity to vascular structures, acute bleeding after spontaneous 
rupture or due the patient's general ill-health. In such situations, arterial embolization has been 
reported as an option in the literature to control acute bleeding, manage symptoms, and to 
shrink hemangiomas prior to surgical resection70-71. Branches of the hepatic artery are 
embolized with substances like fat , gel foam , bleomycin or polyvinyl alcohol  
 
Bozkaya H et al72 in 2014 described successful embolization with bleomycin mixed with lipiodol 
of 32 symptomatic giant haemangiomas in 26 patients [21 female, five male; age 41-65 years 
(mean 49.83 ± 1.53)] who were otherwise unfit for surgical intervention. Angioembolization 
results in shrinkage of the lesion, thereby minimizing the risk of complications. The recognized 
complications of this procedure include pain, fever, abscess formation and non-granulomatous 
arteritis with eosinophilic infiltration .The long-term success rate of embolization (without 
subsequent surgical resection) is however not well studied as yet. 
 
Radiotherapy 
Hepatic irradiation with a dose of 15-30 Gy in 15-22 fractions over several weeks has been used 
to treat symptomatic haemangiomas .Reports are published in literature since 1960s  and the 
techniques of delivery have significantly  improved  over last decade .This modality is  however 
generally reserved for unresectable lesions  as it required months to deliver the required 
fractions of therapy.  Tumour regression and symptom relief is noted in most patients, with 
minimal morbidity 73-76. 
 
Radiofrequency ablation 
In recent years, radiofrequency ablation (RFA) has emerged as a safe, feasible, and effective 
technique for treatment of giant symptomatic hepatic cavernous haemangiomas. Mode of 
delivery is through percutaneous, open surgical and laparoscopic routes. Van Tilborg et al77 
reported successful management of 4 patients with a large-volume, symptomatic hepatic 
cavernous haemangioma of >10 cm were treated with bipolar RFA during laparotomy with 
ultrasound guidance. Peri-procedural shrinkage of the lesions was remarkable and 
intermediate-term volume reduction ranged from 58-92% after 6 months. Symptom relief after 
6 months was complete in two patients (50%) and considerable in the other two (50%). 
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Fan et al 78  presented a study of a total of 68 patients, 18 males and 50 females, age 43.1 (30-
64), with 104 hepatic haemangiomas ,  2.5-11 cm in diameter ( mean size = 5.6 cm), who were 
treated by ultrasound-guided RFA, via percutaneous (n = 19), laparoscopic (n = 29), or open 
surgical (n = 20) approach. In 7 patients with hepatic lesions larger than 7 cm in diameter, 
Pringle’s manoeuvre was used to occlude the hepatic blood flow during the laparoscopic and 
open RFA therapy. The authors concluded that RFA therapy to be a safe, feasible and effective 
treatment option and that hepatic inflow occlusion by Pringle’s manoeuvre can reduce the blood 
loss and increase the therapeutic efficacy significantly. 
 
Fan  et al 79 presented the results of  another series  of  30 patients treated by RFA therapy after 
suture and ligation surgery (SL group, n = 15, with 18 liver lesions) or RFA therapy without 
suture and ligation surgery (non-SL group, n = 15, with 17 liver lesions) and concluded that RFA 
therapy combined with suture and ligation surgery is a safe, feasible, and effective treatment 
modality for giant hepatic haemangiomas  and that it can reduce blood loss, shorten RFA 
therapy time, and increase therapeutic efficacy of RFA. 
 
Role of Biopsy 
 Due to the advances and wide availability of a range of diagnostic imaging modalities and the 
complications of biopsy including rupture, the imaging-guided biopsy of haemangioma is 
usually not resorted to, except in extremely atypical cases 1. 
 
Hepatic haemangiomas in pregnancy  
Inspite of growth promoting influence of estrogens on hepatic haemangiomas8, the lesions 
generally behave indolently during pregnancy and can be observed 80. However, there are rare 
reports in literature, where intervention was required on emergent basis due to complications 
like rupture and coagulopathy 81.  
 
Summary  
Hepatic haemangiomas are the commonest benign tumours of liver. They are usually diagnosed 
incidentally. Imaging modalities have made the diagnosis specific in recent years .They 
generally remain asymptomatic and do not require any active intervention or prolonged follow-
up. For symptomatic, undefined or complicated lesions, surgical management is the main stay of 
therapy though other newer, less invasive modalities have come up in last few decades. 
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